Home » Newsletters » BioWorld Science

BioWorld Science

May 27, 1999

View Archived Issues

MGI Pharma expands ovarian cancer trial with MGI-114

Additional findings announced for Avax Technologies' cancer vaccine

Techniclone initiates phase I/II trial of TNT for solid tumors, reports phase I brain cancer results

Suntory seeks approval of Adenoscan in Japan

Biogen's Amevive shows excellent results in phase II psoriasis study

Maxim completes first two marketing agreements for Maxamine

Hyseq identifies new IL-1 gene

Novel immunomodulatory peptide from SangStat prevents chronic transplant rejection

Update of PNU-145156E phase I trial presented at ASCO meeting

NPS Pharmaceuticals' calcimimetic enters Japanese development

SangStat presents new PKC modulator that inhibits transplant rejection in mice

Valentis to merge with PolyMASC

CoCensys and Parke-Davis collaboration yields development compound

Cephalon's narcolepsy treatment available in Austria

Antiacne drug candidate available for licensing from Shire

New dose of Baycol approved in the U.S. for treatment of hypercholesterolemia

Novo Nordisk receives positive opinion from CPMP on rapid-onset insulin product

Use of ET antagonists for transplant rejection described by Knoll

Japanese patent covers new microbially produced antifungal substance discovered at Sankyo

Banyu describes new neuropeptide Y5 receptor antagonists

Antalarmin suppresses stress-related behavior in nonhuman primate model

New taxanes from Yakult Honsha possess excellent antitumor activity

Inhibitors of prenyltransferases designed by BMS researchers

Dopaminergic and serotonergic ligands in development at Sanofi-Synthelabo

News from APA: Adderall has significant advantages over Ritalin in treatment of ADHD

Preliminary efficacy, tolerability reported for DEHOP in AIDS-related cancer patients

Heterocycles useful in the treatment of BPH disclosed by Ortho-McNeil

Antiidiotype cancer vaccine induces immune response and may delay disease progression in MBC

Preliminary results show good tolerance for LEP in patients with advanced NSCLC

LED proceeds to phase II trials in prostate cancer due to acceptable toxicity, evidence of efficacy

Encouraging phase I trials results for Prostvac presented at ASCO

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...